Dr. Horn on Monitoring Response and Resistance to Ensartinib in ALK+ NSCLC
Ensartinib in Melanoma Press Release. Please click on the link below for details. You can find more information on this and other Ensartinib trials on the clinicaltrials.gov website.
Xcovery Announces Initiation of Phase 2 Clinical Trial for Ensartinib in Melanoma Patients with ALK Alternations
Check out our recent article posted on OncLive highlighting the promising activity observed with our investigational ensartinib agent! https://lnkd.in/eMTwb-i
Xcovery is presenting a poster entitled: eXalt3: First-Line Ensartinib (X396) versus Crizotinib in Advanced ALK-Rearranged NSCLC (eXalt3): A Randomized, Open-Label, Phase 3 Study Yi-Long Wu, Tony S. Mok, Martin Reck, Heather A. Wakelee, Chris Liang, Fenlai Tan, Kimberly Harrow, Vance Oertel, Gary Dukart, Lieming Ding, Leora Horn The overall study objective is to evaluate the efficacy and safety of ensartinib vs crizotinib in patients with […]
Xcovery is presenting a mini-oral presentation entitled: Response to Ensartinib in TKI naïve ALK+ NSCLC patients Heather A. Wakelee, Rachel E. Sanborn, Jorge Nieva, Saiama Naheed Waqar, Christina E. Brzezniak, Jessica Bauman, Joel W. Neal, Gary Dukart, Fenlai Tan, Kimberly Harrow, Chris Liang, Leora Horn Ensartinib has shown clinical activity in patients harboring an ALK […]